<SEC-DOCUMENT>0001193125-23-261829.txt : 20231025
<SEC-HEADER>0001193125-23-261829.hdr.sgml : 20231025
<ACCEPTANCE-DATETIME>20231024190625
ACCESSION NUMBER:		0001193125-23-261829
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20231024
FILED AS OF DATE:		20231025
DATE AS OF CHANGE:		20231024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		231343651

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d903397d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated October 24, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d903397dex991.htm">Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023. </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October 24, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d903397dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g903397dsp4a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Reports Promising Clinical Data from <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> Trial </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>at ESMO Congress 2023 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Promising efficacy and tolerability reported from efti plus <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy and doublet chemotherapy as first line therapy in metastatic <FONT STYLE="white-space:nowrap">non-squamous</FONT> <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer continues
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strong 71.4% Overall Response Rate, 90.5% Disease Control Rate,
<FONT STYLE="white-space:nowrap">10.1-month</FONT> median Progression Free Survival (PFS), and median Overall Survival (OS) that has not been reached, despite 81% of patients having low or negative <FONT STYLE="white-space:nowrap">PD-L1</FONT>
expression </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> <FONT
STYLE="white-space:nowrap">PD-L1</FONT> TPS &lt;50% patient population, the triple combination achieved a high 70.6% response rate and median PFS that exceeded 10 months in both low and negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> patients
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-small</FONT> cell lung cancer patients with low or negative <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression (TPS &lt;50%) represent roughly 65% of the overall patient population and remain an area of high unmet need </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 24</B><B></B><B>&nbsp;October 2023 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today provides an overview of the promising clinical data from the
investigator-initiated <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> trial. The study evaluates a triple combination of eftilagimod alpha (&#147;efti&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II
agonist, with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy (pembrolizumab) and doublet chemotherapy (carboplatin/pemetrexed) as front-line therapy for metastatic or advanced <FONT
STYLE="white-space:nowrap">non-squamous</FONT> <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prof. Dr.&nbsp;Salah-Eddin
Al-Batran of the Frankfurt Institute of Clinical Cancer Research IKF and project lead stated: &#147;Our broad experience evaluating efti across numerous solid tumour indications as monotherapy and in combination with immune checkpoint inhibitors has
furthered our understanding of the complementary mechanisms of action at play with this novel MHC class II agonist. We are building deeper insights into how efti jumpstarts the immune system to fight cancer through activation of dendritic cells, and
its synergy with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. Now with this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IO-IO-chemotherapy</FONT></FONT> combination,
cytotoxic CD8+ T cells that are activated and significantly proliferate via efti can be armed with chemo-induced tumour antigens to drive an even greater immune response. We&#146;re seeing early yet powerful results, especially in low and negative <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expressing patients in need of new therapies to combat cancer.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The poster presentation at ESMO Congress
2023 showed the triple combination therapy continues to be well-tolerated with strong signals of efficacy. The clinical data<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> included a positive median Overall Survival (OS) that was not reached
and encouraging median Progression Free Survival (PFS) of 10.1 months. Additionally, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IO-IO-chemo</FONT></FONT> combination achieved a 71.4% Overall Response Rate (ORR) 90.5%
Disease Control Rate (DCR), and showed positive early trends in <FONT STYLE="white-space:nowrap">12-month</FONT> OS and PFS rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notably, 81% (17/21)
of patients in the trial had a <FONT STYLE="white-space:nowrap">PD-L1</FONT> Tumor Proportion Score (TPS) of &lt;50%, including <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative (TPS &lt;1%) and <FONT STYLE="white-space:nowrap">PD-L1</FONT> low
(TPS <FONT STYLE="white-space:nowrap">1-49%),</FONT> who are less responsive to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> based therapy as compared to <FONT STYLE="white-space:nowrap">PD-L1</FONT> high
(TPS <U>&gt;</U>50%) patients. In this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> NSCLC patient population with <FONT STYLE="white-space:nowrap">PD-L1</FONT>
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g903397dsp4a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
TPS &lt;50%, the triple combination&#146;s 70.6% ORR <FONT STYLE="white-space:nowrap">10.9-month</FONT> median PFS (TPS <FONT STYLE="white-space:nowrap">1-49%)</FONT> and 10.1 month median PFS
(TPS &lt;1%) compare favourably to the reported 40.8% response rate, <FONT STYLE="white-space:nowrap">9.2-month</FONT> median PFS (TPS <FONT STYLE="white-space:nowrap">1-49%),</FONT> and <FONT STYLE="white-space:nowrap">6.2-month</FONT> median PFS
(TPS &lt;1%) from a registrational trial of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and doublet chemotherapy.<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> Furthermore, the triple combination
appears to be safe, and the addition of efti does not appear to increase the toxicity of the standard chemo-immunotherapy regimen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Best Overall Response from Baseline by <FONT STYLE="white-space:nowrap">PD-L1</FONT> Status </U></B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g903397g1024171859670.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep CSO, Dr.&nbsp;Fr&eacute;d&eacute;ric Triebel, said: &#147;Immutep continues to prioritise <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, one of the largest cancer indications globally, as the most significant area of focus in our late-stage development pipeline. The compelling data that our proprietary MHC Class&nbsp;II
agonist has generated in combination with immune checkpoint inhibitors for NSCLC patients positions efti as one of the more promising clinical candidates in immuno-oncology today. This is applicable regardless of patient <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression, and particularly in patients with negative or low <FONT STYLE="white-space:nowrap">PD-L1</FONT> levels who typically respond poorly to checkpoint treatment and for which we see strong potential
with this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IO-IO-chemo</FONT></FONT> combination.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients with high, low, and
negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression represent approximately 30%, 35%, and 35%, respectively, of the metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer patient population. Unlike many
immuno-oncology (IO) combinations that focus on high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expressing patients, compelling clinical results to date from efti&#146;s clinical trials suggest it may be uniquely positioned to effectively address
low and high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expressors through chemo-free <FONT STYLE="white-space:nowrap">IO-IO</FONT> combinations, and potentially the entire NSCLC patient population with a focus on patients with TPS &lt;50% with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IO-IO-chemo</FONT></FONT> combinations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
<FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is an investigator-initiated study conducted
by the <U>Frankfurt Institute of Clinical Cancer Research IKF</U>. It is being run as the third arm (Stratum C) of the ongoing Phase I INSIGHT trial with Prof. Dr.&nbsp;Salah-Eddin Al-Batran as lead investigator. The study is evaluating a triple
combination therapy in front line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer patients consisting of efti administered subcutaneously in conjunction with an existing approved <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy (pembrolizumab) and chemotherapy (carboplatin and pemetrexed) delivered
intravenously. The trial will assess the safety, tolerability, and initial efficacy of the combination. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g903397dsp4a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT
STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy
and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>According to RECIST1.1 (data <FONT STYLE="white-space:nowrap">cut-off</FONT> of August&nbsp;1, 2023).
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Journal of Clinical Oncology 2020 38:14, 1505-1517, Updated Analysis From
<FONT STYLE="white-space:nowrap">KEYNOTE-189:</FONT> Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non&#150;Small-Cell Lung Cancer </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g903397dsp4a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g903397dsp4a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .6UGQ>
MEE.UM91K-(APSL?E!]/>LI5+:(Y*N)47:)2L_%>KR30JUE'.LI.Q4!!;'7'-
M2JDNQG'$5&UH=98WT5_ 9(PRLIVNC##(PZ@BMD[G9":DKHM4RPH * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 5=2BN)M,N8K23R[AXV$;9QAL<4 <[X*TO6]-6[_M61MCD>6CR;SGG)[X[4
M =90 4 % !0 4 % !0 4 % !0 4 % !0!QFE^-YM3\2QZ8MDD41=U+ER3\H/
MM[4 =G0 4 % !0 4 % #9(UEB>-QE&!4CU!H$U=6//)]*;0+^26X$QC0%K:6
M,9&[MN]*YG'E9YSI^RE=_(SSJFIW=S$QN99I4/R <\_2IYFS+VDY-:G9^%M%
METZ*2ZNABYG_ (?[H_QK>$;:L[J%)P5Y;LZ*M#I"@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H S]=_Y 5]_UQ;^53+X69U?@9S'@3_CZ
MO?\ <7^9K*EU.3";LH:Y_P CB_\ UVC_ )+4R^,SJ_QON.^OXUET^YC895HV
M!'X5T/8]&2O%HX?P0Q&LR*#P83G\Q6%+<X,+\9M^-HU;1HW(^9)A@_4&KJ[&
M^*7N7'>"F)T)@>TS ?I3I?"/"_PSG/#O_(VQ_P"_)_(UE#XCEH_Q3J_%D:OX
M=N"1RA5A['(_QK:I\)V8A?NV9O@1C]DO$["12/R_^M44MC+";,J>.HU%W9R
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZ,2S#Z$]* -:@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_P#(HVG^\_\ Z$: .DH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MNOUHYI![2KW8?VOK?_/W=?K1S2#VE7NP_M?6_P#G[NOUHYI![2KW8?VOK?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
, 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g903397g1024171859670.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g903397g1024171859670.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #K B<# 2(  A$! Q$!_\0
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ME#Y:N06)=F)P, 98DX   '0"L[3?^1RUW_KA:_RDK>K!TW_D<M=_ZX6O\I*
M-ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MD;?0[N[>^>YNI5M8]0EN(K3R0-S Y4[NI&>>*ZZB@#B+!KR^3P^NG6LB7.G6
MA$TEY;R11J3&J[,D MD\\9^[]*U-*NQ!J6HV5['.MS<7(8&.WE\ILQ1@D/C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\T\7_%G_A%?$EQI']C?:?*5&\W[
M3LSN4'IM/K7I=9]UH6CWUPT]WI5C<3, #)-;H[''3DC-1-2:]UV.C#3HPG>M
M'F7W'D__  OS_J7?_)S_ .PKUV*XFO=(BN;81QS3PK(@DRRJ6&><8SC-5/\
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M\ABQ_P"OB/\ ]"%<<L3)2M8^DI9+2G1C4<GJK].Q]B4445V'S84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7)ZYXWCT759+%K!Y2@4[Q(!
MG(STQ765G7>@:5?7+7%U80RS, "[#DXZ4F<V*A7E"U"2B_/L<G_PLV''_(*D
M_P"_P_PKK[G4'@T9M0BLYKEA$)%MX0"[9[#\ZJ_\(IH/_0+M_P#OFM9$6-%1
M %50  .PH5S/"4\5!OZQ-2[67_ .4N-6U&]T>VO8+VSC7[?"DR6VYF"F1%\L
MEL$-R<_*..,=Z@O;S5=-U>Z6Y>Z:"XE5HUB=7+('&!&O&W.40YQDDGM76SVE
MO=1[)HE9=ZR8Z?,I!4_@0/RJ*[TJROUF6Y@$GG(J.=Q!PIR,$'(P3G(IG:36
MES%>VD-U 28ID#H2,<$9%34R&&.W@CAA0)%&H5%4<*!P!3Z "BBB@ HHHH *
M*** "BBB@ HHHH **** "O-+0I_PE%S]I-N91J3!//:Y,F-_&"OR8].WK7I=
M<'''KMWK<KVLUW+LOR#<I>K]F2)6YC,77<%^7IUYS0!WE<EJYFN_$+V:V%S'
M:Q 3M+%;MF[GV$(OF8VJ%XY8]<#H#GK:* .2\.V,KZ?=6,-QK-M9"*%89+HX
MFC<#YPI<=!A1TQG=BG>'X!I_BW7K62^NKN006LA>Y(+;3Y@ZJ ,<&NKK!TW_
M )'+7?\ KA:_RDH ^=?B%J%KJOCC4;^RD,EM/Y;1N5*Y&Q1T(!'(K$TD9UFQ
M [W$?_H0KI/BG_R4G5_]Z/\ ]%K7-:5_R&+'_KXC_P#0A7ES_B/U/O<-_NL/
M\*_(^KSXDTI='DU4W+?8HY3"\GE/D.'\LC;C/WN.GOTJT^I6D>JQ:8TA%W+$
MTR)L."BD G.,=6'&:MT5ZA\$9;>(M+73=0U W#?9=/D>.Y?RG^1D^\,8R<>V
M:L2:K9Q7EE:/*1/>AFMUV-\X4;CSC X/?%7** ,]=;T]QJ16<G^S21=?NV^0
MA0_I\WRG/&:0Z[IPATV4SMLU)E6U/EM\Y92XSQ\O /7%:-% %.+5+.:_O+))
M2;BS5&G78PVA@2O.,'@'IFJR>(M+?2['4EN&-K?2)%;OY3Y=G.%&,9'/J!6K
M10!474K1]6DTQ9";R.%9V38<!&) .<8Z@\9S53_A)=)_L4:O]I;["9?*$GDO
MG=O\O&W&?O<9Q[]*UJ* *C:E:+JT>EF0_;)(6G6/8V"@(4G=C'4CC.:JMXDT
MI-*OM3:X86EC(\5P_DOE&0X88QDX/H#6K10!3EU2SAO[.R>4BXO%=H%V,=P4
M MSC X(ZXJ(:YIQBU*43MLTUF6Z/EM\A"ASCCYOE(/&:T:* ,]M;T]1II,QQ
MJ1 M?W;?.2A?T^7Y03SBGQZK92W=]:I*3-8A3<+L;Y R[ASC!X';-7:* ,M?
M$.EMIVGWXN&^S:A(D=L_E/\ .S_=&,9&??%64U.TDU6;3$E)O(8EFDCV-PC$
M@'.,'E3QFK=% &3_ ,)+I)T:/5_M+?89)1$DGE/DL7V ;<9^]QT]^E6SJ5H-
M672S*?MC0&X$>P_<#!2<XQU(XSFK=% &4WB32DTF\U1KEA9V<CQ3R>4^59&V
ML,8R>?0&K,NJ6<.HVNGR2D75TCO"FQCN"8W<XP.HZU<HH S?[>TW[+J5S]H/
MDZ:[)=-Y3?NRJAFXQEN".F:>^LV"2:=&TQ#:CG[*/+;Y\+O]/E^49YQ5^B@"
MBFL6,D^H0),3)I^/M(\MODRNX=N>/3-1#Q!IALM-O!<'R-2=$M6\I_G9QE1C
M&5R!WQ6G10!4CU.TFU2XTU)2;NWC265-C#:K9VG.,'H>AJH/$FDMH\&K"Y;[
M%<2+%')Y3Y+,^P#;C(^;CD5K44 5/[2M/[6_LOS3]L\C[1Y>PX\O=MSG&.O;
M.:JMXDTI='N-5-RWV*VD:*63RGRK*^PC;C)^;C@5JT4 5)-2M(M3M].>0BZN
M(WEB38Q#*N-QSC ^\.IJN=?TT66HWAG;R--=TNF\I_D9 "V!C+8!'3-:=% %
M)]7LHY["!IB)-0S]F'EM\^%W'G'''KBFIK-A)+J$2S$OIV/M0\MODRN[T^;C
MGC-7Z* ,W^W]--IIMUY[>3J3HEJWE/\ .64LN1C*Y /7%3Q:G:3:E<Z<DI-U
M;(DDJ;& 57SM.<8/W3T-6Z* ,I?$FE/I-KJBW+&SNY$BAD\I\LS-M48QD<]R
M*M#4K0ZLVEB0_;%@%P8]AQL+;<YQCJ.F<U;HH RCXDTH:-)JQN6^PQ2F)Y/*
M?(8/L(VXS][CI[]*M/J5I'JL.F/(1=S1-,B;#@HI )SC Y8<9JW10!F'Q#I@
MT_4+XW#?9].=X[I_*?Y&3EAC&6Q[9J:35K**ZL;9Y2);X,;==C?/M7<><8''
MKBKM% %!=9L'.HA9C_Q+CBZ_=M\GRA_3YOE.>,TW^W-.\C39O//EZDRK:GRV
M^<LI8=OEX!ZXK1HH IQZI9S7]Y8I*3<6:H\Z;&&T,"5YQ@\ ],U77Q%I;Z78
MZDMRQM+Z1(K=_*?YV<X48QD9/J!6I10!474K1M6DTL2G[9'"L[1[#PA) .<8
MZ@\9S53_ (272?[%;5_M+?85E\HR>2^=V_R\;<9^]QT]^E:U% %1]2M$U6+3
M&E(O)86G2/8V"BD G.,=2.,YJLWB+2UTR_U$W#?9;"1XKE_*?Y&3[PQC)Q[
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M256*LF>J45XPUHA=7,UX63.T_;)LC/7^*O2K'PII%K*+J**Y$K.LN6O)F&X
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M4E;U8.F_\CEKO_7"U_E)0!O4444 %%%% !1110 4444 %%%% !1110 4444
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M^C^.M-UJ\TZVM[>Z4WUOYT;NJ[%^_A203R1&Y&,C Z\B@"__ &OJ?_0MW_\
MW_M__CE']KZG_P!"W?\ _?\ M_\ XY6S6?J>L0:5-8131S.U[<"WC,:9"L03
MECT XH K?VOJ?_0MW_\ W_M__CE']KZG_P!"W?\ _?\ M_\ XY6S4<\C1022
M)$\K*I(C3&YO89(&?J10!E?VOJ?_ $+=_P#]_P"W_P#CE']KZG_T+=__ -_[
M?_XY533?&=EJ=_86B6=["U[!YT;2HH5>&(4X8\E49AC(QCGFNDH QO[7U/\
MZ%N__P"_]O\ _'*/[7U/_H6[_P#[_P!O_P#'*?XA\0VOAO3TO+J&>96D\L)
MH9ONEB>2. JL?PK55@ZAE.5(R#0!C_VOJ?\ T+=__P!_[?\ ^.4?VOJ?_0MW
M_P#W_M__ (Y6S60/$5D?%+>'@'^V+;"Y8DJ%VDD #)R3QV!QQF@!O]KZG_T+
M=_\ ]_[?_P".4?VOJ?\ T+=__P!_[?\ ^.5LUE:QKL&BS:>EQ!.ZWMPMNLD:
M@JC'INR0>?;)X)[4 1_VOJ?_ $+=_P#]_P"W_P#CE']KZG_T+=__ -_[?_XY
M4F@:];^(;!KNW@N(5639LG4!C\H93P3P593^-:M &-_:^I_]"W?_ /?^W_\
MCE']KZG_ -"W?_\ ?^W_ /CE.D\0VL?B:+0S#/YTD>X3!1Y8;!8(3G.=JL>F
M..M:] &-_:^I_P#0MW__ '_M_P#XY1_:^I_]"W?_ /?^W_\ CE:TLB0Q/+(<
M(BEF/H!6;X>U^V\1Z:;VVAGA4.4:.=0K X!'0D<AE/XT 1_VOJ?_ $+=_P#]
M_P"W_P#CE']KZG_T+=__ -_[?_XY6S61K'B&UT2YL8;B&>0W<FP-$H(C&Y5W
M-STW.@XR>?K0 W^U]3_Z%N__ ._]O_\ '*/[7U/_ *%N_P#^_P#;_P#QRMFH
M;N<VMI-.L$LYC0L(H@"[X[ '')H S/[7U/\ Z%N__P"_]O\ _'*/[7U/_H6[
M_P#[_P!O_P#'*IZ1XUL-9OK.U@MKM#=0>:LCJNP,,Y0D$\X!.1D$=ZZ6@#&_
MM?4_^A;O_P#O_;__ !RC^U]3_P"A;O\ _O\ V_\ \<INM^)[70+F".\MKDPR
MH[?:$52BE49]N,Y)PC'@'WQFKFC:K%K6F1WT4,L(8LK13 !T96*L#@D<$'H:
M *O]KZG_ -"W?_\ ?^W_ /CE']KZG_T+=_\ ]_[?_P".5LUD:;XBLM4UK4]+
MMQ()].94F+%0"2,\#.['N0!G- #?[7U/_H6[_P#[_P!O_P#'*/[7U/\ Z%N_
M_P"_]O\ _'*V:Q]7\266BZEIMC<AS-?LRQ[2H"A0,DY(SU' R?;B@!/[7U/_
M *%N_P#^_P#;_P#QRC^U]3_Z%N__ ._]O_\ '*DT#78/$.G?;;>"X@4/M,<Z
M@,. P/!/!5E/XUJT 8W]KZG_ -"W?_\ ?^W_ /CE']KZG_T+=_\ ]_[?_P".
M5GS^/=)AEV+'=2J+YK(R1Q@J"H3<_7[@,BC([] 174T 8W]KZG_T+=__ -_[
M?_XY1_:^I_\ 0MW_ /W_ +?_ ..5+KVN0^'].6]N+>XFA\U(V\A02FXXW')'
M&<#UR0 *9H_B"VUF[O[:&&XB>SDV,95 $@W,H9<$\;D<<X/'2@!O]KZG_P!"
MW?\ _?\ M_\ XY1_:^I_]"W?_P#?^W_^.5LUCW?B.TLO$5GHLD4YGNDW"14!
MC3.[:&.<Y.Q\8!Z<XH 3^U]3_P"A;O\ _O\ V_\ \<H_M?4_^A;O_P#O_;__
M !RMFLOQ!KUIX;T>74[P.T2,JA4(!9F( &6( Y/4D"@"+^U]3_Z%N_\ ^_\
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M2,NN""0<T =/16/IGB.RU6ZC@@616F@:XB+@8= ^TGKQU4X/9Q[T4 ;%%%%
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M4.W!['.*\_L_#7BG3?$EE.]W=W%B)X'D$=Q*?)4[]R*'D.Y,A=^[)PWR],4
M>H5DZOX=T_6[JRN+U9"UF^] CE0W(.&'<;E4X]5%:U<1XTT37=8U)#I=Y<VD
M45C(PEAD8'S0ZD*H# %B 1E@0 30!TFA:%:>'M.^Q633-'O+EII"['@ <GL
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
